CRISPR在新冠肺炎诊断和治疗中的应用

4区 生物学 Q2 Medicine
Methods in Microbiology Pub Date : 2022-01-01 Epub Date: 2022-05-06 DOI:10.1016/bs.mim.2022.03.002
Pallavi Deol, Aashwina Madhwal, Gaurav Sharma, Rahul Kaushik, Yashpal Singh Malik
{"title":"CRISPR在新冠肺炎诊断和治疗中的应用","authors":"Pallavi Deol, Aashwina Madhwal, Gaurav Sharma, Rahul Kaushik, Yashpal Singh Malik","doi":"10.1016/bs.mim.2022.03.002","DOIUrl":null,"url":null,"abstract":"<p><p>Since the beginning of the COVID-19 pandemic, many diagnostic approaches (RT-qPCR, RAPID, LFA) have been adopted, with RT-qPCR being the most popular/gold standard. But, one of the major problems of COVID-19 diagnostics is the presentation of a wide range of symptoms which varies among different patients and needs early diagnosis for better management. Even though RT-qPCR is a precise molecular technique false negative results may be obtained. On the other hand, CRISPR-based SARS-CoV-2 detection approaches are cost and time efficient, highly sensitive and specific, and do not require sophisticated instruments. Moreover, they also show promise for increased scalability and diagnostic tests can be carried out at the point-of-care (POC). The CRISPR can be customized to the target of any genomic region of interest within the desired genome possessing a broad range of other applications and has been efficiently implemented for diagnosis of SARS-CoV-2. The CRISPR/Cas systems provide the specific gene targeting with immense potential to develop new generation diagnostics and therapeutics. Moreover, with the CRISPR/Cas based therapeutics, multiplexing is possible, where different sgRNAs or crRNAs can be guided to more than one target within the same gene thus decreasing the possibility of viral escape mutants. As an exceptionally efficient tool CRISPR/Cas13 and CARVER (Cas13-assisted restriction of viral expression and readout) systems can be implemented to target a broad range of ssRNA viruses that can be used for both, diagnosis and treatment for a variety of viral diseases including SARS-CoV-2. However, the efficacy and safety of the CRISPR-based therapeutics needs to be assessed in pre-clinical and clinical settings. Although the CRISPR biotechnologies are not very helpful to control the present pandemic of COVID-19 it is hopeful that the limitations of the CRISPR/Cas system can be overcome in the near future. The CRISPR based strategies may lead to a new era in the field of disease diagnosis and therapeutic development that would make us better prepared for future viral threats.</p>","PeriodicalId":49823,"journal":{"name":"Methods in Microbiology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9073596/pdf/","citationCount":"2","resultStr":"{\"title\":\"CRISPR use in diagnosis and therapy for COVID-19.\",\"authors\":\"Pallavi Deol, Aashwina Madhwal, Gaurav Sharma, Rahul Kaushik, Yashpal Singh Malik\",\"doi\":\"10.1016/bs.mim.2022.03.002\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Since the beginning of the COVID-19 pandemic, many diagnostic approaches (RT-qPCR, RAPID, LFA) have been adopted, with RT-qPCR being the most popular/gold standard. But, one of the major problems of COVID-19 diagnostics is the presentation of a wide range of symptoms which varies among different patients and needs early diagnosis for better management. Even though RT-qPCR is a precise molecular technique false negative results may be obtained. On the other hand, CRISPR-based SARS-CoV-2 detection approaches are cost and time efficient, highly sensitive and specific, and do not require sophisticated instruments. Moreover, they also show promise for increased scalability and diagnostic tests can be carried out at the point-of-care (POC). The CRISPR can be customized to the target of any genomic region of interest within the desired genome possessing a broad range of other applications and has been efficiently implemented for diagnosis of SARS-CoV-2. The CRISPR/Cas systems provide the specific gene targeting with immense potential to develop new generation diagnostics and therapeutics. Moreover, with the CRISPR/Cas based therapeutics, multiplexing is possible, where different sgRNAs or crRNAs can be guided to more than one target within the same gene thus decreasing the possibility of viral escape mutants. As an exceptionally efficient tool CRISPR/Cas13 and CARVER (Cas13-assisted restriction of viral expression and readout) systems can be implemented to target a broad range of ssRNA viruses that can be used for both, diagnosis and treatment for a variety of viral diseases including SARS-CoV-2. However, the efficacy and safety of the CRISPR-based therapeutics needs to be assessed in pre-clinical and clinical settings. Although the CRISPR biotechnologies are not very helpful to control the present pandemic of COVID-19 it is hopeful that the limitations of the CRISPR/Cas system can be overcome in the near future. The CRISPR based strategies may lead to a new era in the field of disease diagnosis and therapeutic development that would make us better prepared for future viral threats.</p>\",\"PeriodicalId\":49823,\"journal\":{\"name\":\"Methods in Microbiology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9073596/pdf/\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Methods in Microbiology\",\"FirstCategoryId\":\"99\",\"ListUrlMain\":\"https://doi.org/10.1016/bs.mim.2022.03.002\",\"RegionNum\":4,\"RegionCategory\":\"生物学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2022/5/6 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Methods in Microbiology","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1016/bs.mim.2022.03.002","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/5/6 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 2

摘要

自2019冠状病毒病大流行开始以来,采用了许多诊断方法(RT-qPCR、RAPID、LFA),其中RT-qPCR是最流行的/金标准。但是,COVID-19诊断的主要问题之一是表现出广泛的症状,这些症状因患者而异,需要早期诊断以更好地管理。尽管RT-qPCR是一种精确的分子技术,但也可能出现假阴性结果。另一方面,基于crispr的SARS-CoV-2检测方法具有成本和时间效率高,灵敏度高,特异性强,不需要复杂的仪器。此外,它们还有望提高可扩展性,并且可以在护理点(POC)进行诊断测试。CRISPR可以针对期望基因组中任何感兴趣的基因组区域进行定制,具有广泛的其他应用,并已有效地用于SARS-CoV-2的诊断。CRISPR/Cas系统为开发新一代诊断和治疗方法提供了巨大的潜力。此外,使用基于CRISPR/Cas的治疗方法,多重复用是可能的,其中不同的sgrna或crrna可以被引导到同一基因内的多个靶点,从而降低了病毒逃逸突变的可能性。作为一种非常有效的工具,CRISPR/Cas13和CARVER (Cas13辅助限制病毒表达和读出)系统可以用于广泛的ssRNA病毒,这些病毒可以用于诊断和治疗包括SARS-CoV-2在内的各种病毒性疾病。然而,基于crispr的治疗方法的有效性和安全性需要在临床前和临床环境中进行评估。虽然CRISPR生物技术对当前新冠病毒大流行的控制并不是很有帮助,但CRISPR/Cas系统的局限性有望在不久的将来被克服。基于CRISPR的策略可能会导致疾病诊断和治疗开发领域的新时代,这将使我们更好地为未来的病毒威胁做好准备。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
CRISPR use in diagnosis and therapy for COVID-19.

Since the beginning of the COVID-19 pandemic, many diagnostic approaches (RT-qPCR, RAPID, LFA) have been adopted, with RT-qPCR being the most popular/gold standard. But, one of the major problems of COVID-19 diagnostics is the presentation of a wide range of symptoms which varies among different patients and needs early diagnosis for better management. Even though RT-qPCR is a precise molecular technique false negative results may be obtained. On the other hand, CRISPR-based SARS-CoV-2 detection approaches are cost and time efficient, highly sensitive and specific, and do not require sophisticated instruments. Moreover, they also show promise for increased scalability and diagnostic tests can be carried out at the point-of-care (POC). The CRISPR can be customized to the target of any genomic region of interest within the desired genome possessing a broad range of other applications and has been efficiently implemented for diagnosis of SARS-CoV-2. The CRISPR/Cas systems provide the specific gene targeting with immense potential to develop new generation diagnostics and therapeutics. Moreover, with the CRISPR/Cas based therapeutics, multiplexing is possible, where different sgRNAs or crRNAs can be guided to more than one target within the same gene thus decreasing the possibility of viral escape mutants. As an exceptionally efficient tool CRISPR/Cas13 and CARVER (Cas13-assisted restriction of viral expression and readout) systems can be implemented to target a broad range of ssRNA viruses that can be used for both, diagnosis and treatment for a variety of viral diseases including SARS-CoV-2. However, the efficacy and safety of the CRISPR-based therapeutics needs to be assessed in pre-clinical and clinical settings. Although the CRISPR biotechnologies are not very helpful to control the present pandemic of COVID-19 it is hopeful that the limitations of the CRISPR/Cas system can be overcome in the near future. The CRISPR based strategies may lead to a new era in the field of disease diagnosis and therapeutic development that would make us better prepared for future viral threats.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Methods in Microbiology
Methods in Microbiology 生物-生化研究方法
CiteScore
1.50
自引率
0.00%
发文量
15
审稿时长
>12 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信